You are here

Umbilical Cord MSCs for COVID‐19 ARDS

Researchers led by Camillo Ricordi (University of Miami Miller School of Medicine, Miami, FL, USA) recently reported the results of a double‐blind, randomized, controlled, early-phase clinical trial of umbilical cord mesenchymal stem cell (MSC) treatment in subjects with COVID‐19 acute respiratory distress syndrome. Lanzoni et al. note fewer serious adverse events in the treatment compared to the control group, while exploratory efficacy analyses provide evidence of significantly improved patient survival and time to recovery. These findings strongly support further investigation in a larger trial to estimate and establish efficacy and influence clinical practice and future research in the fields of acute respiratory distress syndrome, COVID‐19, and other immune‐related disorders. For more details, see STEM CELLS Translational Medicine now!